Thus, once antigen-loaded DCs migrate to dLNs, they can present tumor antigens to T cells, resulting in generation of either immunity or immune tolerance (18, 37), depending on whether TiDCs are properly matured to express high levels of co-stimulatory molecules (e.g. CD80, CD83, CD86) and immunostimulatory cytokines (37). The gene discussed is CD83; the disease is neoplasm.